

Non-Financial Information

Name of Organization:

VIVA FOUNDATION FOR CHILDREN WITH CANCER

Registered Address:

**8 Sinaran Drive
#03-01 VIVA-CCF Hub
Singapore 307470**

Contact Information:

Telephone No., 65 6694 3370

Fax. No.. 65 6694 3372

Email Address, admin@viva.sg

Website Address, www.viva.sg

Directory

Unique Entity Number (UEN)	:	200601578E
Charity Registration Number	:	01961
Current IPC Effective Period	:	15 May 2013 – 14 May 2016
HEF Registration Number	:	HEF 0105/G
Bankers	:	Citibank Singapore Ltd Oversea-Chinese Banking Corporation Ltd
Auditors	:	Moore Stephens LLP

Board of Directors

<u>Name</u>	<u>Position</u>	<u>Date of Appointment</u>
Foo-Yo Mie Yoen Theresa	Chairman	6 February 2006
Leong Lai Peng	Director/Secretary	6 February 2006
Christina Ong @Christina Fu	Director	6 February 2006
Kwee Liong Keng	Director	6 February 2006
Koh Seow Chuan	Director	20 October 2006
Lee Ming San	Director	20 October 2006
Kuok Oon Kwong	Director	9 November 2007
Mary Ann Wai Sheng Tsao	Director	21 August 2008
Tan Wah Yeow	Director	1 September 2010

Mission:

“Saving lives of children with cancer through excellence in medical care, research, an education”

Viva Foundation for Children with Cancer (“Viva”) was set up on 6 February 2006 and registered with the Accounting and Corporate Regulatory Authority (ACRA) as a Company Limited by Guarantee. Viva was also registered under the Charities Act on 25 April 2006. It has Institution of Public Character (IPC) status and has been a member of Health Endowment Fund since 8 May 2006.

Objectives

The goal of Viva is to improve the survival rate and cure of children with cancer, especially childhood leukaemia, in Singapore and around the region. Viva Foundation hopes to achieve this by facilitating a partnership between St Jude Children’s Research Hospital (“St Jude”) in Memphis, Tennessee, USA, and National University Hospital, Singapore (“NUH”) and National University of Singapore (“NUS”). It is hoped that the children’s cancer centre established by Viva Foundation in NUH will become a world class centre for the treatment of paediatric cancers adopting state-of-the-art medical practices in terms of organization, clinical treatment, care and research.

Viva Programs

Viva-University Children’s Cancer Centre (VUC³)

Viva established the VUC³ which is housed in Ward 8B (formally ward 88), Kent Ridge Wing in the National University Hospital. It is a one-stop centre with state-of-the-art transplant facilities; complete with the inpatient wards and outpatient consultation and day therapy areas so that every child with cancer will receive most of their care in a holistic treatment environment. This facility is the seat of the St. Jude-Viva International Outreach Program to train local and regional doctors and nurses and the Viva Foundation’s Centre of Excellence for the treatment of childhood cancer. VUC³ was officially opened in February 2008. Since its opening, VUC³’s continues to be busy, at times over-flowing. Its expanding reputation can be seen by a growing number of complex referral cases and participation in clinical research. For children covered in the Malaysian-Singapore clinical trial, the average cure rate of leukemia of 80% was achieved, close to Viva’s aspiration of the 90% cure rate at St Jude’s Hospital. To complement the VUC³’s facilities, the VIVA-Goh Foundation program also sponsors dedicated manpower and training.

The number of patient cases seen at the VUC³ is summarized over the following pages:

FY2012 Annual Report

Figure 1 Total Number of Cases versus Oncology Cases 2006 - 2012




Figure 2 Incidence of Cases – Local versus Foreign Patients 2006 – 2012




Figure 3 Patient Admissions to VUC³ 2006 - 2012





Figure 4 Blood and Marrow Transplants 2006 – 2012



Clinical Research Program

One of Viva's foremost aims is to improve cure rates for childhood cancers through fostering research and enabling novel therapies through the strategic setting-up of critical facilities. In 2012, VIVA successfully raised funds for an unrivalled leukaemia research and diagnostics laboratory in Asia. The facility will combine molecular, flow-cytometry and cellular therapies under one roof and will include tissue banking. We are in the midst of aligning different stake holders so that we can launch the project in 2013/2014. There are currently three areas of focused clinical research:

- **Molecular:** New equipment and facilities will allow Viva to run a state-of-art trial in treating childhood acute myeloid leukaemia by participating in the St Jude AML 2008 study. VUC³ will be the first centre outside USA to accrue patients directly into a St Jude trial.
- **Flow-based MRD:** This will allow us to accurately predict the risk of relapse in almost every child with leukaemia
- **Cellular-Based Therapy:** In Singapore, our small families limit the chances of finding a matched donor for stem cell transplantation; Viva will thus enhance local capability of alternative stem cell transplantation using matched unrelated donors and haploidentical transplantation from parents. Through this program, we hope more children who lack a matched sibling donor can be offered a chance of cure.

In 2011, Viva Foundation funded the St. Jude AML 08 study in VUC³ which incorporates many new exciting therapies like haploidentical natural killer cells to eradicate residual leukemia cells. Currently there are 2 patients enrolled on this trial.

St Jude-Viva International Outreach Program

This program aims to develop regional centres of excellence in ASEAN countries, through collaboration and sharing of knowledge with doctors and nurses around the region and through providing training here in Singapore.

This is achieved by identifying, gaining an understanding of the local issues and helping to coordinate the establishment of these centres. The St Jude-Viva International Outreach program will provide hands-on and systematic training of foreign doctors and nurses from the region at NUHS for 1-3 years. The trainer program will comprise a core team of up to two doctors and four nurses, each being trained in Singapore and deployed at their respective centres. The centres will establish their own pediatric oncology programs, and support themselves through fundraising by their local charities. The first such program is at the Davao Medical Centre in the Philippines.

Nurses working in the field of childhood cancer are continuously challenged by the diverse age, personal needs and strengths of each family as well as requiring the theoretical knowledge and complex practical skills for the different types of childhood cancer and treatment. We have established a pediatric haematology and oncology program for registered nurses to give them the specialist skills and expertise required to care for children with cancer. This benefits not only local nurses, but also students from the region such as Davao, Philippines. Clinical attachments in nursing are also available.

St Jude-Viva Forum in Paediatric Oncology

This annual forum is the primary platform for top doctors and scientists from all over the world to exchange information and collaborate on translational clinical research in childhood cancer. Interaction between participants is extended through Pre-Forum workshops focused on issues uniquely relevant to participants from countries in the region. The sixth annual St Jude-Viva Forum in Pediatric Oncology was held at the Shangri-La Hotel, Singapore from March 2nd to 4th 2012. The Opening Ceremony was held on 2nd

FY2012 Annual Report

March with Guest of Honour, Minister for Health, Mr GAN Kim Yong. The presentations at the Forum were from 13 world experts from the USA, Germany, Israel, The Netherlands and Singapore. The total attendance at the Forum was 261, from Australia, Hong Kong, India, Indonesia, Japan, Korea, Kyrgyzstan, Malaysia, Myanmar, New Zealand, Peoples Republic of China, Philippines, Qatar, Saudi Arabia, Singapore, Sri Lanka, Taiwan, Thailand and Vietnam.

Three important ongoing initiatives at the Forum are the Viva-Asia Acute Leukaemia (VAWGM), the Viva-Asia BMT (VABMT) Working Groups and the Pre-Forum Workshop.

- The VABMT aims to learn more about each others' centres and has been exploring and implementing opportunities to work together in research and strategic planning in pediatric BMT in the region.
- The VAWGM aims for clinicians, scientists and researchers to meet and develop ideas to standardise, collaborate and support each other. Eventually the hope is that VAWGM is able to coordinate common questions and indications for research, training and standards, translating care of childhood leukaemia therapy to Asia.
- The Pre-Forum Workshop aims for clinicians from developing countries to meet and discuss the current status of paediatric oncology programs at their centres and common problems faced within the group. A panel of regional and international experts are represented in the faculty and as speakers.

All meetings aim to enhance regional collaboration and provide the opportunity to learn from each other's experience. For the Viva-Asia Working Groups, leaders from the major Asian cooperative groups will be invited to look at their data and present it in a small group meeting of Asian leaders in this meeting. For the Pre-Forum, the group aim to undertake common or joint projects. These opportunities encourage close collaboration and expand the St Jude-Viva Forum from a passive learning event to an active collaborative Forum.

Viva-CCF Hub at 8 Sinaran Drive

The Viva-CCF Hub is a unique opportunity for Singapore's private, public and philanthropic sectors to work together. These new premises also allow VIVA to bring together other groups and volunteers. As a designated civic and community space, VIVA, the Children's Cancer Foundation (CCF) and the Singapore Cord Blood Bank (SCBB) operate out of this VIVA-CCF Hub at a cost-recovery basis. Working together with our colleagues synergistically at the Hub allows us to enhance services to children with cancer through shared resources and further coordination of activities and programs. This is particularly important for patient, family and community education and awareness.

For example, to help children recovering from cancer with their schooling and integrate back into the community, the Hub was specially renovated to allow for an infectious disease controlled space. As a result, the children can attend structured academic and therapy programs at the VIVA-CCF hub, under a program run by CCF.

Financial Information

Viva Foundation received resources amounting to S\$1.1m in 2012.

Total expenses for 2012 was S\$1.1m. Nearly all of the expenses were related to the donated premises which we are now occupying, e.g. non-recoverable GST, depreciation and maintenance fees.

As a result, Viva recorded a net deficit of S\$197.00 for 2012.

INCOME & EXPENDITURE	2010 '000	2011 '000	2012 '000	% Increase/(Decrease) [2012 vs 2011]
Income				
Donations in Cash				
Tax-Deductible	665	2,022	888	-56.1%
Non Tax-Deductible		0	14	6750.9%
Donations in Kind				
Tax-Deductible		24,100		-100.0%
Non Tax-Deductible	2	-		
Grants	9	10		-100.0%
Sponsorships		-		
Investment Income	5	5	6	20.1%
Investment Gains	-	-		
Programme Fees & other receipts	83	73	141	94.0%
Others	1			
Total Income	765	26,210	1,049	-96.0%
Expenses				
Direct Fund-raising Expenses	20	-	-	0.0%
Charitable Activities Expenses				
Local	0	1	390 ¹	47811.1%
Overseas	-	-	-	
Other Operating & Admin Expenses	68	1,644 ²	660 ³	-59.8%
Others	0			
Total Expenditure	89	1,645	1,050	-36.2%
Surplus / (Deficit)	676	24,565	(0)	-100.0%

Footnotes:

1. Local charitable expenses refer to non-claimable GST input tax, maintenance fees for Viva Hub and expenses incurred of St. Jude-Viva Forum 2012.
2. Non-claimable GST input tax related to the gift of space at 8 Sinaran Drive (earlier named Viva Hub); maintenance fees for Viva Hub and other governance costs.
3. In 2012, Viva increased its number of employees from one to two. It also incurred additional moving expenses and fixed overheads, associated with the new premises, e.g. depreciation expense.

BALANCE SHEET	2010	2011	2012	%
	'000	'000	'000	Increase/(Decrease) [2012 vs 2011]
Assets				
Land and Buildings	-	23,739	23,257	-2.0%
Other Tangible Assets	2	1	444 ¹	64162.2%
Investments	-	-	-	
Inventories	1	-	-	
Accounts Receivables & prepayments	22	10	579 ²	5831.6%
Cash & Deposit	3,732	4,578	4,090	-10.7%
Others				
Total Assets	3,756	28,327	28,369	0.2%
Funds				
Unrestricted	3,745	28,310	28,310	0.0%
Restricted	-	-	-	
Endowment Fund	-	-	-	
Total Funds	3,745	28,310	28,310	0.0%
Liabilities				
Long-Term Liabilities				
Current Liabilities	11	16	59	262.2%
Total Liabilities	11	16	59	262.2%
Total Funds and Liabilities	3,756	28,327	28,369	0.2%

Footnotes:

1. In October 2012, Viva moved into the new premises at #03-01, 8 Sinaran Drive, which was gifted by Far East Organization in 2011. The increase includes furniture and fittings associated with the renovations at the new premises.
2. Viva paid for the renovation expenses, MCST fees and utilities associated with the new premises at #03-01. Viva's licensees were subsequently invoiced for their share of these expenses at cost as outlined in the licensing agreement terms.

OTHER INFORMATION	2010	2011	2012	% Increase/(Decrease) [2012 vs 2011]
Donations/Grants and Sponsorships given to other Charities	0	180,000 ¹	0	-100.0%
No. of Employees	1	1	2	100.0%
Total Employee Costs	51,884	52,263	118,211	126.2%
Total Related Party Transactions ²	0	0	0	
Fund-raising efficiency ³	3%	0%	19%	100.0%
Ratio of reserves to annual operating expenditure ⁴	54	17	27	56.7%

Footnotes:

1. In 2011, S\$180,000 was paid to NUS-Viva Education and Research Fund (NUS-VERF) associated with the St Jude-Viva Forum in that year.
2. Related Party Transactions refer to transactions between the IPC and another person where either person could have influence over the other. For example, if a board member of an IPC is related to a certain supplier of services for the IPC, the value of the transactions should be disclosed. Refer to the Financial Reporting Standards for the full definition of Related Party Transactions.
3. Fund-raising Efficiency. This is expressed in the ratio of A to B, where A refers to Direct Fund-raising Expenses and sponsorships relating to fund-raising (where receipts have been issued by sponsors); and B refers to total donations received from fund-raising and sponsorships relating to fund-raising (where receipts have been issued by sponsors).
4. Ratio of reserves to annual operating expenditure. This is expressed in the ratio of C to D, where C refers to Unrestricted Funds; and D refers to Charitable Activities Expenses and Other Operating and Administration Expenses.